Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-29T15:59:36.126Z Has data issue: false hasContentIssue false

Chapter 6 - The Secret behind India’s Success in Pharmaceuticals

Seizing the Right Windows of Opportunity

from II - Sectoral studies

Published online by Cambridge University Press:  05 July 2014

Shyama V. Ramani
Affiliation:
United Nations University, Tokyo
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Innovation in India
Combining Economic Growth with Inclusive Development
, pp. 186 - 210
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

ABLE (Association of Biotechnology Led Enterprises)-BioSpectrum. 2009. The Seventh Survey of Indian Biotech Industry (Volume 7). ABLE, India. Accessed: 3 September 2013; http://www.ableindia.in/pdf/seventh_biospectrum_survey_june_09.pdf.Google Scholar
Achilladelis, B. and Antonakis, N.. 2001. ‘The Dynamics of Technological Innovation: The Case of the Pharmaceutical Industry.Research Policy 30 (4): 535–88.CrossRefGoogle Scholar
Ahmad, H. 1988. Technological Development in Drugs and Pharmaceutical Industry in India. New Delhi: Navrang.Google Scholar
Athreye, S., Kale, D., and Ramani, S. V.. 2009. ‘Experimentation with Strategy and the Evolution of Dynamic Capability in the Indian Pharmaceutical Sector.Industrial and Corporate Change 18 (4): 729–59.CrossRefGoogle Scholar
Basheer, S. 2008. ‘Ranbaxy-Daiichi Merger: An Emerging Ardhnarishwar Model?Sify Finance, 10 July. Accessed: 3 September 2013; http://sify.com/finance/fullstory.php?id=14712790.Google Scholar
Burton, H. J. 1998. ‘A Reconsideration of Import Substitution.Journal of Economic Literature 36: 903–36.Google Scholar
CCI (Corporate Catalyst India). 2007. A Brief Report on Pharmaceutical Industry in India. New Delhi: CCI. Accessed: 3 September 2013; http://www.cci.in/pdfs/surveys-reports/Pharmaceutical-Industry-in-India.pdf.Google Scholar
Chakma, J. H., Masum, K., Perampaladas, J., Heys, J., and Singer, P. A.. 2010. ‘India’s Billion Dollar Biotech.Nature Biotechnology 28 (8): 783.CrossRefGoogle ScholarPubMed
Chaturvedi, S. 2007. ‘Exploring Inter linkages between National and Sectoral Innovation Systems for Rapid Technological Catch-Up: Case of Indian Biopharmaceutical Industry.Technology Analysis and Strategic Management 19 (5): 643–59.CrossRefGoogle Scholar
Chaturvedi, S. 2005, 2006. ‘Dynamics of Biotechnology Research and Industry in India.’ OECD Science, Technology and Industry Working Papers 2005/6. Paris: OECD Publishing. Accessed: 3 September 2013; http://www.oecd.org/science/sci-tech/34947073.pdf.Google Scholar
Chaudhuri, S. 2007. ‘Is Product Patent Protection Necessary in Developing Countries for Innovation? R & D by Indian Pharmaceutical Companies after TRIPS.’ Indian Institute of Management Working Paper Series: WPS No. 614/September 2007. Calcutta: Indian Institute of Management.Google Scholar
Chaudhuri, S. 2005. The WTO and India's Pharmaceuticals Industry. New Delhi: Oxford University Press.Google Scholar
Edquist, C. 1997. Systems of Innovation: Technologies, Institutions and Organizations. London: Pinter.Google Scholar
Freeman, C. 1995. ‘The National System of Innovation in Historical Perspective.Cambridge Journal of Economics 19 (1): 524.Google Scholar
Gehl-Sampath, P. 2008. India's Pharmaceutical Sector in 2008: Emerging Strategies and Global and Local Implications for Access to Medicines. London: Department for International Development (DFID).Google Scholar
Greene, W. 2007. ‘The Emergence of India's Pharmaceutical Industry and Implications for the U.S. Generic Drug Market.’ Office of Economics Working Paper. Washington, DC: US International Trade Commission.Google Scholar
Guennif, S. and Ramani, S.. 2012. ‘Explaining Divergence in Catching-Up in Pharma between India and Brazil using the NSI Framework.Research Policy 41 (2): 430–41.CrossRefGoogle Scholar
Kale, D. and Little, S.. 2007. ‘From Imitation to Innovation: The Evolution of R&D Capabilities and Learning Processes in the Indian Pharmaceutical Industry.Technology Analysis and Strategic Management 19 (5): 589611.CrossRefGoogle Scholar
Kaushal, L. M. 2007. ‘Drug Price Control Order and Recent Developments.New Delhi: NPPA. Accessed: September, 19 2010; http://pharmexcil.com/data/uploads/5.DrugsPriceControlOrderandRecentDevelopments.pdf.Google Scholar
Lall, S. 1974a. ‘International Pharmaceutical Industry and Less-Developed Countries: II: Costs and Alternatives.Economic and Political Weekly 9 (48): 1990–96.Google Scholar
Lall, S. 1974b. ‘The International Pharmaceutical Industry and Less-Developed Countries, with Special Reference to India.Oxford Bulletin of Economics and Statistics 36 (3): 143–72.CrossRefGoogle Scholar
Lundvall, B. A. E. 1992. National Innovation Systems: Towards a Theory of Innovation and Interactive Learning. London: Pinter.Google Scholar
Malerba, F. 2002. ‘Sectoral Systems of Innovation and Production.Research Policy 31 (2): 247–64.CrossRefGoogle Scholar
Malerba, F. and Orsenigo, L.. 2002. ‘Innovation and Market Structure in the Dynamics of the Pharmaceutical Industry and Biotechnology: Towards a History-Friendly Model.Industrial and Corporate Change 11 (4): 667703.CrossRefGoogle Scholar
McKelvey, M., Orsenigo, L., and Pammolli, F.. 2004. ‘Pharmaceuticals Analyzed through the Lens of a Sectoral Innovation System.’ In Sectoral Systems of Innovation: Concepts, Issues and Analyses of Six Major Sectors in Europe, edited by Malerba, F., 73120. Cambridge, UK: Cambridge University Press.CrossRefGoogle Scholar
Nelson, R. 1993. National Innovation Systems: A Comparative Analysis. Oxford: Oxford University Press.CrossRefGoogle Scholar
OPPI. 2001, 2004. Organisation of Pharmaceutical Producers of India: Pharmaceutical Compendium. Mumbai: OPPI.Google Scholar
Ramani, S. V. and Maria, A.. 2005. ‘TRIPS and its Possible Impact on the Biotech Based Segment of the Indian Pharmaceutical Industry.Economic and Political Weekly 40 (7): 675–83.Google Scholar
Ramani, S. V. 2002. ‘Who's Interested in Biotechnology: R&D Strategies, Knowledge Base and Market Sales of Indian Biopharmaceutical Firms.Research Policy 31 (3): 381–98.CrossRefGoogle Scholar
Ramani, S. V. and Venkataramani, M. S.. 2001. ‘Rising to the Technological Challenge: Integration of Biotechnology in the Indian Pharmaceutical Industry.International Journal of Biotechnology 3 (1/2): 95115.CrossRefGoogle Scholar
Redwood, H. 1994. New Horizons in India. Suffolk. England: Oldwicks Press Limited.Google Scholar
Reid, S. and Ramani, S.. 2010. The Harnessing of Biotechnology in India: What Are the Roads to Market Heaven? Online Publishing: Mimeo.Google Scholar
Silverman, E. 2011. ‘India may Cap Foreign Direct Investment in Pharma.Pharmalot. Accessed: June 2012; http://www.pharmalive.com/india-may-cap-foreign-direct-investment-pharma.Google Scholar
Singh, N. 2008. ‘A Win Win Deal.Biospectrum (India). Accessed: 19 September 2010; http://biospectrumindia.ciol.com/content/BioBusiness/10807111.asp.Google Scholar
Singh, S. 1985. Multinational Corporations and Indian Drug Industry. New Delhi: Criterion Publications.Google Scholar
Soete, L. 1985. ‘International Diffusion of Technology, Industrial Development and Technological Leap frogging.World Development 13 (3): 409–22.CrossRefGoogle Scholar
Srinivasan, S. 2007. ‘Battling Patent Laws: The Glivec Case.Economic and Political Weekly 42 (37): 3686–91.Google Scholar
Tribune des droits de l'homme. 2007. L’industrie Indienne N’aide Pas Les Indiens (The Indian Industry does not help Indians). Accessed: 3 September 2013; http://www.infosud.org/La-pharma-indienne-n-aide-pas-les,2152.Google Scholar
Waning, B., Diedrichsen, E., and Moon, S.. 2010. ‘A Lifeline to Treatment: The Role of Indian Generic Manufacturers in Supplying Antiretroviral Medicines to Developing Countries.Journal of the International AIDS Society 13 (35): 110.CrossRefGoogle ScholarPubMed
WHO. 2010. W.H.O. List of Prequalified Medicinal Products. Accessed: October 2010; http://who.int/prequal/.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×